Natera, Inc.
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Total Contract Liabilities — Deferred Revenue by Quarter
Total Contract Liabilities — Deferred Revenue ($M) ($M)
Natera Total Contract Liabilities — Deferred Revenue: $56.6M in Q2 2026, up 48.9% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (2026-08-07) ↗
Total current and noncurrent contract liabilities (deferred revenue) from biopharma clinical trial milestones, licensing agreements, and prepayments ($64.25M at Q2 2026).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Contract Liabilities — Deferred Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 56.6 | +48.9% | Form 10-Q (2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 53.9 | +44.6% | Form 10-Q (2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 42.0 | +14.7% | Form 10-Q (2026-08-07) ↗ |
| Q3 2025 | Sep 30, 2025 | 38.2 | +9.9% | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 38.1 | +3.5% | Form 10-Q (2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 37.3 | +2.0% | Form 10-Q (2026-05-08) ↗ |
| Q4 2024 | Dec 31, 2024 | 36.6 | +2.4% | Form 10-Q (2026-08-07) ↗ |
| Q3 2024 | Sep 30, 2024 | 34.8 | -3.5% | Form 10-Q (2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 36.8 | -1.0% | Form 10-Q (2025-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 36.5 | -4.1% | Form 10-Q (2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 35.7 | +16.1% | Form 10-K (2026-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 36.1 | +27.2% | Form 10-Q (2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 37.2 | +1.1% | Form 10-Q (2024-08-09) ↗ |
| Q1 2023 | Mar 31, 2023 | 38.1 | +10.5% | Form 10-Q (2024-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 30.8 | +7.2% | Form 10-K (2025-02-28) ↗ |
| Q3 2022 | Sep 30, 2022 | 28.3 | -12.4% | Form 10-Q (2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 36.7 | +7.4% | Form 10-Q (2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 34.5 | +4.8% | Form 10-Q (2023-05-10) ↗ |
| Q4 2021 | Dec 31, 2021 | 28.7 | -60.6% | Form 10-K (2024-02-29) ↗ |
| Q3 2021 | Sep 30, 2021 | 32.4 | -56.5% | Form 10-Q (2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 34.2 | -54.3% | Form 10-Q (2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 32.9 | -57.3% | Form 10-Q (2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 72.9 | -8.6% | Form 10-K (2023-03-01) ↗ |
| Q3 2020 | Sep 30, 2020 | 74.4 | -9.2% | Form 10-Q (2020-11-06) ↗ |
| Q2 2020 | Jun 30, 2020 | 74.9 | -6.0% | Form 10-Q (2020-08-07) ↗ |
| Q1 2020 | Mar 31, 2020 | 77.0 | +72.5% | Form 10-Q (2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 79.8 | +80.6% | Form 10-K (2021-02-26) ↗ |
| Q3 2019 | Sep 30, 2019 | 81.8 | +115.3% | Form 10-Q (2019-11-08) ↗ |
| Q2 2019 | Jun 30, 2019 | 79.7 | +113.6% | Form 10-Q (2019-08-09) ↗ |
| Q1 2019 | Mar 31, 2019 | 44.6 | – | Form 10-Q (2019-05-10) ↗ |
| Q4 2018 | Dec 31, 2018 | 44.2 | +3,012.0% | Form 10-K (2020-03-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 38.0 | – | Form 10-Q (2018-11-09) ↗ |
| Q2 2018 | Jun 30, 2018 | 37.3 | – | Form 10-Q (2018-08-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 1.42 | – | Form 10-K (2019-03-15) ↗ |
Breakdown
What makes up total Contract Liabilities — Deferred Revenue
- Deferred Revenue, Current ($M)40.6 · Q2 2026
- Deferred Revenue, Long-Term / Noncurrent ($M)16.1 · Q2 2026
- Contract Liability Roll-Forward: Additions / Deferrals in Period ($M)26.4 · Q2 2026
- Contract Liability Roll-Forward: Revenue Recognized from Beginning Balance ($M)-11.8 · Q2 2026
- Contract Liability Roll-Forward: Revenue Recognized from Same-Period Deferrals ($M)-11.8 · Q2 2026
- BGI Genomics License Agreement — Current Contract Liability ($M) [legacy through Q3 2025]0.50 · Q3 2025
- BGI Genomics License Agreement — Noncurrent Contract Liability ($M) [legacy through Q3 2025]16.4 · Q3 2025
- Foundation Medicine Collaboration — Current Contract Liability ($M) [legacy through Q3 2025]1.70 · Q3 2025
- Genetic Testing Services — Current Contract Liability ($M) [legacy through Q3 2025]19.6 · Q3 2025
- BGI Genomics Remaining Performance Obligations — RPO ($M) [legacy through Q1 2025]6 · Q1 2025
- Qiagen Licensing Remaining Performance Obligations — RPO ($M) [legacy through Q3 2019]40 · Q3 2019
Cite this data
StockData. (2026). Natera Total Contract Liabilities — Deferred Revenue ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/contract-liab-total
See every metric in the Natera KPI table. Data updated Nov 2, 2026.